查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1803472

Cas9 核酸酶市場按類型、規格、交付方式、應用、最終用戶和治療領域分類——2025-2030 年全球預測

Cas9 Nuclease Market by Type, Format, Delivery Method, Application, End User, Therapeutic Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Cas9 核酸酶市場預計在 2024 年達到 6.0245 億美元，2025 年達到 6.5619 億美元，到 2030 年達到 10.1595 億美元，複合年成長率為 9.09%。

主要市場統計數據
基準年2024年 6.0245億美元
預計2025年 6.5619億美元
預測年份 2030 10.1595億美元
複合年成長率（%） 9.09%

探索 Cas9 核酸酶技術在重塑基因編輯、治療創新和下一代基因組學研究方面的關鍵作用和演化。

在過去十年中，Cas9 核酸酶已成為現代基因組編輯的基石，使研究人員能夠以前所未有的精度靶向特定的 DNA 序列。這種源自細菌免疫系統的革命性工具加速了基礎研究、藥物開發和治療創新的探索步伐。隨著科學家不斷完善 Cas9 介導的切割機制，Cas9 在促進基因工程突破方面的能力將無與倫比。

揭示正在改變 Cas9 核酸酶市場格局和研究前沿的突破性技術進步和策略支點

隨著Cas9核酸酶領域的日益成熟，新一輪變革正在重新定義研究人員和產業領導者的策略重點。高保真Cas9變異體的創新顯著減少了非預期的基因組修飾，增強了人們對治療應用的信心。同時，Cas9死融合體的出現釋放了精準表觀表觀基因編輯與轉錄調控的潛力，拓展了功能基因體學的視野。

分析美國新關稅對 Cas9 核酸酶供應鏈、成本結構和全球研究合作的連鎖影響

2025年美國新關稅的實施，為Cas9核酸酶的供應鏈和成本結構帶來了顯著的曲折點。套件和試劑、質體載體、純化蛋白以及核糖核蛋白複合物等組件通常來自海外供應商，我們看到到岸成本的調整對採購預算產生了連鎖反應。為此，各組織正在重新評估籌資策略，以在控制成本和持續獲取關鍵試劑之間取得平衡。

闡述關鍵細分見解，重點在於不同類型、格式、遞送方法和治療領域的 Cas9 核酸酶應用

了解Cas9核酸酶細分的細微差別，可以揭示涵蓋酵素類型、製備形式、遞送方式、應用、最終用戶和治療重點領域的多維市場模式。根據類型，死Cas9的存在釋放標靶表觀基因編輯應用，而高保真Cas9變體對於最大限度地減少脫靶事件至關重要。同時，切口酶Cas9和野生型Cas9在需要單鏈或已確定的雙鏈的應用中仍發揮各自的作用。

檢驗美洲、歐洲、中東和非洲以及亞太地區的區域動態在塑造 Cas9 核酸酶的採用和成長方面發揮的關鍵作用

區域動態在塑造Cas9核酸酶的應用方面發揮關鍵作用，每個地區都展現出獨特的優勢和考量。在美洲，強大的資金籌措機制和完善的研究基礎設施正在加速基因編輯技術的開發和商業化。領先的學術中心和生物技術叢集持續試點創新應用，為新試劑和工具的開發者創造了一個競爭激烈的環境。

重點介紹推動 Cas9 核酸酶技術發展和市場競爭力突破的關鍵創新者和策略夥伴關係

Cas9 核酸酶的競爭格局由成熟的生命科學供應商和靈活的生物技術公司共同構成。領先的創新者正在推出工程變體和最佳化的遞送試劑，引發了一波授權合約和戰略夥伴關係關係的浪潮。工具供應商和製藥公司之間的合作研究正在加速基因編輯療法的臨床前開發，彰顯了該產業對轉化影響力的全面承諾。

為行業領導者提供策略建議，以最佳化對 Cas9 核酸酶研究的投資、促進創新並應對監管和市場變化

產業領導者可以透過制定兼顧創新與營運韌性的策略，充分利用 Cas9 核酸酶的強勁發展勢頭。多樣化的酵素變體和製備形式組合，使研究項目能夠靈活應對不斷變化的科研需求。投資高保真度和切口酶版本，同時保留野生型和失活 Cas9 的可用性，可以將使用案例從精準鹼基校正擴展到轉錄調控。

詳細的調查方法概述了 Cas9 核酸酶市場情報報告的數據收集、檢驗過程和分析框架

該報告採用嚴謹的原始研究與全面的二手數據分析相結合的調查方法，提供可靠的市場情報。對分子生物學家、製程開發科學家和臨床研究負責人的專家訪談，提供了新興趨勢和營運挑戰的第一手見解。這些定性研究結果與同行評審的論文、專利申請和監管披露進行了交叉核對，以確保準確性和背景資訊。

結論性見解強化了 Cas9 核酸酶在基因編輯和治療創新中應用的策略重點和未來前景

摘要，Cas9 核酸酶生態系統正在快速發展，其改良變體可增強特異性，多樣化的遞送平台可提高安全性和有效性，而新穎的應用則可拓展科學和臨床效用。美國關稅變化正在推動戰略供應鏈的調整，而美洲、歐洲、中東和非洲以及亞太地區的區域優勢則繼續塑造全球採用模式。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 遞送技術的快速進步提高了 Cas9 的特異性並減少了脫靶效應
  • 鹼基編輯和引子編輯方法的出現擴大了Cas9核酸酶的應用範圍
  • 擴大生技公司與學術機構的夥伴關係，加速Cas9臨床管線建設
  • 使用Cas9核酸酶進行體內基因編輯療法的法規結構不斷發展
  • 擴大高保真 Cas9 變體的應用，以增強治療的安全性
  • 增加對 CRISPR 獨立篩檢平台的投資，以識別新的 Cas9 目標位
  • 透過開發基於 CRISPR-Cas9 的診斷方法實現快速 POC（即時診斷）診斷
  • 利用 Cas9 核酸酶擴展農業基因編輯應用以增強作物性狀

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第8章 Cas9 核酸酶市場（按類型）

  • 死亡Cas9
  • 高保真Cas9
  • 切口酶Cas9
  • 野生型Cas9

9. Cas9 核酸酶市場（依格式）

  • 套件和試劑
  • 質體載體
  • 純化蛋白質
  • 核糖核蛋白複合物

第10章 Cas9 核酸酶市場（依交付方式）

  • 非病毒載體
  • 身體的
  • 病毒載體

第 11 章 Cas9 核酸酶市場（依應用）

  • 鹼基編輯
  • 表觀基因編輯
  • 基因啟用設定
  • 基因敲擊
  • 基因敲除
  • 基因沉默

第 12 章：Cas9 核酸酶市場（依最終使用者）

  • 學術研究機構
  • 生物技術和製藥公司
  • 合約研究組織
  • 醫院和診所

第13章 Cas9 核酸酶市場：依治療領域

  • 血液學
  • 感染疾病
  • 代謝紊亂
  • 神經病學
  • 腫瘤學
  • 眼科

14.美洲Cas9核酸酶市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲Cas9核酸酶市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太地區 Cas9 核酸酶市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • New England Biolabs, Inc.
    • GenScript Biotech Corporation
    • Agilent Technologies, Inc.
    • Promega Corporation
    • Synthego Corporation
    • Addgene, Inc.
    • Takara Bio Inc.
    • Applied Biological Materials Inc.
    • Creative Biolabs
    • CRISPR Therapeutics AG
    • Editas Medicine, Inc.
    • GeneON GmbH
    • Hoelzel Biotech GmbH
    • Horizon Discovery Group by Revvity, Inc.
    • Intellia Therapeutics, Inc.
    • Lonza Group Ltd.
    • Novatein Biosciences Inc.
    • Novoprotein Scientific, Inc.
    • OZ Biosciences SAS
    • SBS Genetech

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-0A380695180E

The Cas9 Nuclease Market was valued at USD 602.45 million in 2024 and is projected to grow to USD 656.19 million in 2025, with a CAGR of 9.09%, reaching USD 1,015.95 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 602.45 million
Estimated Year [2025] USD 656.19 million
Forecast Year [2030] USD 1,015.95 million
CAGR (%) 9.09%

Discover the pivotal role and evolution of Cas9 nuclease technology reshaping gene editing, therapeutic innovation, and next-generation genomic research

The past decade has witnessed Cas9 nuclease emerge as a cornerstone of modern genome editing, enabling researchers to target specific DNA sequences with unprecedented precision. This transformative tool, derived from bacterial immune systems, has accelerated the pace of discovery across basic research, drug development, and therapeutic innovation. As scientists continue to refine the mechanism of Cas9-mediated cleavage, its capacity to drive breakthroughs in genetic engineering remains unparalleled.

In parallel, advancements in enzyme engineering have given rise to specialized variants that bolster specificity and reduce off-target effects. The integration of Cas9 into diverse delivery platforms has broadened the scope of applications, spanning from in vitro gene function studies to in vivo therapeutic interventions. Such technological progression has attracted significant interest across academic laboratories, biotechnology firms, and clinical research organizations.

This executive summary synthesizes the key developments shaping the Cas9 nuclease landscape. By examining dynamic shifts in technology, regulatory influences, segmentation trends, regional drivers, and leading market participants, this report delivers a clear view of strategic opportunities. Readers will gain a concise yet thorough understanding of the critical factors propelling the evolution and adoption of Cas9 nuclease solutions.

Unveiling the groundbreaking technological advances and strategic pivots transforming the Cas9 nuclease market landscape and research frontiers

As the Cas9 nuclease field matures, a new wave of transformative shifts is redefining strategic priorities for researchers and industry leaders alike. Innovations in high fidelity Cas9 variants have markedly reduced unintended genome alterations, catalyzing confidence in therapeutic applications. Simultaneously, the emergence of dead Cas9 fusions has unlocked the potential for precise epigenome editing and transcriptional regulation, expanding the horizons of functional genomics.

Moreover, the adoption of nickase Cas9 formats, which introduce single-strand breaks, has provided an additional layer of control for refined editing outcomes. Researchers are increasingly leveraging purified proteins and ribonucleoprotein complexes to achieve transient, high-efficiency editing while mitigating long-term cellular exposure. At the same time, plasmid vectors and kits & reagents remain foundational for streamlined laboratory workflows.

Delivery methods are also undergoing a paradigm shift, with non-viral and physical techniques offering alternatives to traditional viral vectors. These approaches promise enhanced safety profiles and rapid deployment. In parallel, the application spectrum is broadening from gene knockout experiments to sophisticated base editing and gene activation platforms. Together, these advances are charting a course toward more reliable, flexible, and scalable Cas9 nuclease solutions that will shape the next chapter of genomic science.

Analyzing the cascading effects of new United States tariffs on Cas9 nuclease supply chains, cost structures, and global research collaborations

The introduction of new United States tariffs in 2025 has created a notable inflection point for Cas9 nuclease supply chains and cost structures. Components such as kits & reagents, plasmid vectors, purified proteins, and ribonucleoprotein complexes, which are often sourced from international suppliers, have seen adjustments in landed costs that ripple across procurement budgets. In response, organizations are reassessing their sourcing strategies to balance cost containment with uninterrupted access to critical reagents.

These tariff adjustments have also influenced collaborative research, as cross-border partnerships must navigate evolving import duties on physical and non-viral delivery kits alongside viral vector materials. Contract research organizations and biotechnology firms have initiated localized manufacturing and distribution pathways to mitigate financial exposure. Consequently, supply chain resilience has become a central consideration, prompting investment in regional production hubs and strategic vendor alliances.

Looking ahead, stakeholders are adapting to this new regulatory reality by diversifying supplier portfolios and exploring alternative formats that can reduce dependency on tariff-impacted goods. This proactive stance supports continuity in Cas9 nuclease projects, safeguards research timelines, and maintains momentum in therapeutic discovery and development.

Illustrating critical segmentation insights revealing distinct Cas9 nuclease applications across diverse types, formats, delivery methods, and therapeutic domains

A nuanced understanding of Cas9 nuclease segmentation reveals the market's multi-dimensional landscape across enzyme types, preparation formats, delivery methods, applications, end users, and therapeutic focus areas. Based on Type, the presence of Dead Cas9 has unlocked targeted epigenome editing applications while High Fidelity Cas9 variants have become indispensable for minimizing off-target events. Meanwhile, Nickase Cas9 and Wild Type Cas9 maintain their roles in applications demanding either single-strand breaks or established double-strand cleavage.

Based on Format, laboratory workflows leverage Kits & Reagents for streamlined protocols, Plasmid Vectors for flexible gene construct delivery, Purified Proteins for direct editing with transient exposure, and Ribonucleoprotein Complexes for rapid and precise targeting. In terms of Delivery Method, Non-Viral Vectors, Physical techniques such as electroporation, and Viral Vectors each offer distinct trade-offs in efficiency, safety, and scalability.

Based on Application, the field extends from base editing, which facilitates single nucleotide modifications, to epigenome editing for transcriptional control, as well as gene activation, gene knockin, gene knockout, and gene repression. Based on End User, Academic & Research Institutes continue to drive foundational studies, Biotechnology & Pharmaceutical Companies prioritize therapeutic pipelines, Contract Research Organizations enable large-scale screening and custom services, and Hospitals & Clinics explore clinical and diagnostic adaptations.

Based on Therapeutic Area, Hematology has seen early clinical translation, Infectious Diseases leverage gene disruption strategies, Metabolic Disorders target corrective editing, Neurology explores central nervous system interventions, Oncology focuses on engineered cell therapies, and Ophthalmology pioneers sight-restoring approaches. Through this integrated lens, stakeholders can align their strategies with the most compelling segments and emerging opportunities.

Examining the pivotal role of regional dynamics across Americas, Europe, Middle East & Africa, and Asia-Pacific in shaping Cas9 nuclease adoption and growth

Regional dynamics play a pivotal role in shaping Cas9 nuclease adoption, with each geography exhibiting unique strengths and considerations. In the Americas, robust funding mechanisms and well-established research infrastructure have accelerated the development and commercialization of gene editing technologies. Leading academic centers and biotechnology clusters continue to pilot innovative applications, fostering a competitive environment for new reagent and tool developers.

In Europe, Middle East & Africa, harmonized regulatory frameworks and pan-European research initiatives have cultivated a collaborative ecosystem. Cross-border consortia and funding programs support translational research, bolstering the region's capacity to integrate Cas9 nuclease platforms into precision medicine strategies. Meanwhile, a growing network of clinical centers in the Middle East is exploring gene editing's potential to address region-specific genetic disorders.

The Asia-Pacific region stands out for its manufacturing prowess and rapidly expanding biotech sectors. Local production of kits, vectors, and proteins has reduced lead times and increased cost competitiveness. Simultaneously, emerging markets in Asia are fostering academic and industrial partnerships to accelerate access to Cas9 nuclease technologies, positioning the region as a dynamic contributor to global innovation.

Highlighting leading innovators and strategic partnerships driving breakthroughs in Cas9 nuclease technology development and market competitiveness

The competitive landscape of Cas9 nuclease is defined by a combination of established life science suppliers and agile biotechnology firms. Leading innovators have introduced engineered variants and optimized delivery reagents, spurring a wave of licensing agreements and strategic partnerships. Collaborative research efforts between tool providers and pharmaceutical companies have accelerated preclinical development of gene editing therapeutics, underscoring an industry-wide commitment to translational impact.

At the same time, new entrants are differentiating through proprietary protein engineering approaches and end-to-end service models. These companies offer integrated solutions spanning enzyme production, custom construct design, and hands-on technical support. In parallel, specialized contract research organizations are deepening their expertise in pipeline validation, enabling seamless progression from bench to clinic.

This dynamic environment is further characterized by cross-sector alliances, where academic spin-offs team up with manufacturing partners to scale production of high-fidelity variants and clinically relevant delivery systems. As these collaborations mature, they are expected to enhance supply chain robustness, expand application portfolios, and drive down the barriers to entry for emerging therapeutic modalities.

Strategic recommendations empowering industry leaders to optimize Cas9 nuclease research investments, drive innovation, and navigate regulatory and market shifts

Industry leaders can capitalize on Cas9 nuclease momentum by pursuing targeted strategies that balance innovation with operational resilience. Diversifying the portfolio of enzyme variants and preparation formats ensures that research programs remain nimble in the face of evolving scientific needs. Investing in high-fidelity and nickase versions while retaining access to Wild Type and dead Cas9 expands use cases from precise base corrections to transcriptional regulation.

To mitigate supply chain risks, organizations should explore regional manufacturing partnerships and develop contingency sourcing plans for kits, plasmid vectors, purified proteins, and ribonucleoprotein complexes. Simultaneously, aligning delivery strategies with therapeutic objectives-choosing between non-viral, physical, or viral methods-will enhance the likelihood of clinical translation.

Engaging regulatory bodies early and establishing cooperative research frameworks with academic and contract research partners can streamline development pathways. Finally, focusing on high-growth therapeutic areas such as neurology, oncology, and ophthalmology will position stakeholders at the forefront of the next wave of gene editing breakthroughs.

Detailed methodology outlining data collection, validation processes, and analytical frameworks underpinning the Cas9 nuclease market intelligence report

This report's methodology combines rigorous primary research with comprehensive secondary data analysis to deliver robust market intelligence. Expert interviews with molecular biologists, process development scientists, and clinical research leads provided first-hand insights into emerging trends and operational challenges. These qualitative findings were cross-verified against peer-reviewed publications, patent filings, and regulatory disclosures to ensure accuracy and context.

Segmentation analysis was conducted across enzyme Type, including Dead Cas9, High Fidelity Cas9, Nickase Cas9, and Wild Type Cas9; Format variations spanning Kits & Reagents, Plasmid Vectors, Purified Proteins, and Ribonucleoprotein Complexes; Delivery Methods such as Non-Viral Vectors, Physical, and Viral Vectors; Applications ranging from Base Editing to Gene Repression; End Users comprising Academic & Research Institutes, Biotechnology & Pharmaceutical Companies, Contract Research Organizations, and Hospitals & Clinics; and Therapeutic Areas including Hematology, Infectious Diseases, Metabolic Disorders, Neurology, Oncology, and Ophthalmology.

Regional assessments encompassed the Americas, Europe, Middle East & Africa, and Asia-Pacific to capture geographic drivers. Market participant profiling and competitive mapping were informed by company-released data, strategic partnership announcements, and patent landscapes. Throughout the process, data triangulation and validation steps were employed to maintain integrity and relevance.

Concluding insights reinforcing strategic priorities and future outlook for Cas9 nuclease applications in gene editing and therapeutic innovation

In summary, the Cas9 nuclease ecosystem is advancing at a rapid pace, driven by engineered variants that enhance specificity, diverse delivery platforms that improve safety and efficacy, and new applications that extend its scientific and clinical utility. Tariff changes in the United States have prompted strategic supply chain adjustments, while regional strengths in the Americas, Europe, Middle East & Africa, and Asia-Pacific continue to shape global adoption patterns.

Segmentation insights underscore the importance of aligning enzyme type, format selection, delivery approach, application focus, end user needs, and therapeutic area priorities. Leading companies are forging partnerships and expanding capabilities to meet this complexity, while actionable recommendations highlight the value of diversified portfolios, regulatory engagement, and targeted investments in high-impact research areas.

Together, these findings present a comprehensive view of the factors defining the current and future state of Cas9 nuclease technologies, equipping stakeholders with the intelligence needed to make informed strategic decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid advances in delivery technologies to improve Cas9 specificity and reduce off-target effects
  • 5.2. Emergence of base editing and prime editing modalities to expand Cas9 nuclease applications
  • 5.3. Growing partnerships between biotech companies and academic institutions to accelerate Cas9 clinical pipelines
  • 5.4. Regulatory frameworks evolving for in vivo gene editing therapies using Cas9 nucleases
  • 5.5. Increasing adoption of high-fidelity Cas9 variants to enhance therapeutic safety profiles
  • 5.6. Rising investment in CRISPR agnostic screening platforms to identify novel Cas9 target sites
  • 5.7. Development of CRISPR-Cas9 derived diagnostics for rapid point-of-care genetic disease detection
  • 5.8. Expansion of agricultural gene editing applications using Cas9 nucleases for crop trait enhancement

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cas9 Nuclease Market, by Type

  • 8.1. Introduction
  • 8.2. Dead Cas9
  • 8.3. High Fidelity Cas9
  • 8.4. Nickase Cas9
  • 8.5. Wild Type Cas9

9. Cas9 Nuclease Market, by Format

  • 9.1. Introduction
  • 9.2. Kits & Reagents
  • 9.3. Plasmid Vectors
  • 9.4. Purified Proteins
  • 9.5. Ribonucleoprotein Complexes

10. Cas9 Nuclease Market, by Delivery Method

  • 10.1. Introduction
  • 10.2. Non-Viral Vectors
  • 10.3. Physical
  • 10.4. Viral Vectors

11. Cas9 Nuclease Market, by Application

  • 11.1. Introduction
  • 11.2. Base Editing
  • 11.3. Epigenome Editing
  • 11.4. Gene Activation
  • 11.5. Gene Knockin
  • 11.6. Gene Knockout
  • 11.7. Gene Repression

12. Cas9 Nuclease Market, by End User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Biotechnology & Pharmaceutical Companies
  • 12.4. Contract Research Organizations
  • 12.5. Hospitals & Clinics

13. Cas9 Nuclease Market, by Therapeutic Area

  • 13.1. Introduction
  • 13.2. Hematology
  • 13.3. Infectious Diseases
  • 13.4. Metabolic Disorders
  • 13.5. Neurology
  • 13.6. Oncology
  • 13.7. Ophthalmology

14. Americas Cas9 Nuclease Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Cas9 Nuclease Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Cas9 Nuclease Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Thermo Fisher Scientific Inc.
    • 17.3.2. Merck KGaA
    • 17.3.3. New England Biolabs, Inc.
    • 17.3.4. GenScript Biotech Corporation
    • 17.3.5. Agilent Technologies, Inc.
    • 17.3.6. Promega Corporation
    • 17.3.7. Synthego Corporation
    • 17.3.8. Addgene, Inc.
    • 17.3.9. Takara Bio Inc.
    • 17.3.10. Applied Biological Materials Inc.
    • 17.3.11. Creative Biolabs
    • 17.3.12. CRISPR Therapeutics AG
    • 17.3.13. Editas Medicine, Inc.
    • 17.3.14. GeneON GmbH
    • 17.3.15. Hoelzel Biotech GmbH
    • 17.3.16. Horizon Discovery Group by Revvity, Inc.
    • 17.3.17. Intellia Therapeutics, Inc.
    • 17.3.18. Lonza Group Ltd.
    • 17.3.19. Novatein Biosciences Inc.
    • 17.3.20. Novoprotein Scientific, Inc.
    • 17.3.21. OZ Biosciences SAS
    • 17.3.22. SBS Genetech

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. CAS9 NUCLEASE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL CAS9 NUCLEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. CAS9 NUCLEASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. CAS9 NUCLEASE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. CAS9 NUCLEASE MARKET: RESEARCHAI
  • FIGURE 28. CAS9 NUCLEASE MARKET: RESEARCHSTATISTICS
  • FIGURE 29. CAS9 NUCLEASE MARKET: RESEARCHCONTACTS
  • FIGURE 30. CAS9 NUCLEASE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. CAS9 NUCLEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CAS9 NUCLEASE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CAS9 NUCLEASE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DEAD CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DEAD CAS9, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HIGH FIDELITY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HIGH FIDELITY CAS9, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NICKASE CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NICKASE CAS9, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY WILD TYPE CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY WILD TYPE CAS9, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PLASMID VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PURIFIED PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY RIBONUCLEOPROTEIN COMPLEXES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY RIBONUCLEOPROTEIN COMPLEXES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PHYSICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY PHYSICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY EPIGENOME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY EPIGENOME EDITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE ACTIVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE ACTIVATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE KNOCKOUT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE REPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY GENE REPRESSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CAS9 NUCLEASE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 94. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES CAS9 NUCLEASE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 103. CANADA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. CANADA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. CANADA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 106. CANADA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 107. CANADA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 108. CANADA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 109. CANADA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. CANADA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 111. CANADA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. CANADA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 115. MEXICO CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. MEXICO CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. MEXICO CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 118. MEXICO CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 119. MEXICO CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 120. MEXICO CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 121. MEXICO CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 122. MEXICO CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 123. MEXICO CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. MEXICO CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 125. MEXICO CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 126. MEXICO CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 127. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 130. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 131. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 132. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 133. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 135. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 138. BRAZIL CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 139. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 142. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 143. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 144. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 145. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 150. ARGENTINA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CAS9 NUCLEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED KINGDOM CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 177. GERMANY CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. GERMANY CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. GERMANY CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 180. GERMANY CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 181. GERMANY CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 182. GERMANY CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 183. GERMANY CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 184. GERMANY CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 185. GERMANY CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. GERMANY CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. GERMANY CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 188. GERMANY CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 189. FRANCE CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. FRANCE CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. FRANCE CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 192. FRANCE CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 193. FRANCE CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 194. FRANCE CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 195. FRANCE CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. FRANCE CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 197. FRANCE CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. FRANCE CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. FRANCE CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 200. FRANCE CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 201. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 203. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 204. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 205. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 206. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 207. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 209. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 211. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 212. RUSSIA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 213. ITALY CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. ITALY CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. ITALY CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 216. ITALY CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 217. ITALY CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 218. ITALY CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 219. ITALY CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. ITALY CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 221. ITALY CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. ITALY CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. ITALY CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 224. ITALY CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 225. SPAIN CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. SPAIN CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. SPAIN CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 228. SPAIN CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 229. SPAIN CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 230. SPAIN CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 231. SPAIN CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. SPAIN CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 233. SPAIN CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. SPAIN CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 235. SPAIN CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. SPAIN CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED ARAB EMIRATES CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 251. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 252. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 253. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 254. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 255. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 257. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 259. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 260. SAUDI ARABIA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 261. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 264. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 265. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 266. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 267. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 271. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 272. SOUTH AFRICA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 273. DENMARK CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. DENMARK CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. DENMARK CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 276. DENMARK CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 277. DENMARK CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 278. DENMARK CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 279. DENMARK CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. DENMARK CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 281. DENMARK CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. DENMARK CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 283. DENMARK CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 284. DENMARK CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 288. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 290. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 296. NETHERLANDS CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 297. QATAR CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. QATAR CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. QATAR CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 300. QATAR CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 301. QATAR CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 302. QATAR CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 303. QATAR CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. QATAR CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 305. QATAR CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. QATAR CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. QATAR CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 308. QATAR CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 309. FINLAND CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. FINLAND CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. FINLAND CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 312. FINLAND CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 313. FINLAND CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 314. FINLAND CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 315. FINLAND CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 316. FINLAND CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 317. FINLAND CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. FINLAND CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 319. FINLAND CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 320. FINLAND CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 321. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 324. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 325. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 326. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 327. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 329. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 331. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 332. SWEDEN CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 333. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 335. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 336. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 337. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 338. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 339. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 341. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 343. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 344. NIGERIA CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 345. EGYPT CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. EGYPT CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 347. EGYPT CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 348. EGYPT CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 349. EGYPT CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 350. EGYPT CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 351. EGYPT CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 352. EGYPT CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 353. EGYPT CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. EGYPT CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 355. EGYPT CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 356. EGYPT CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 357. TURKEY CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. TURKEY CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 359. TURKEY CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2018-2024 (USD MILLION)
  • TABLE 360. TURKEY CAS9 NUCLEASE MARKET SIZE, BY FORMAT, 2025-2030 (USD MILLION)
  • TABLE 361. TURKEY CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 362. TURKEY CAS9 NUCLEASE MARKET SIZE, BY DELIVERY METHOD, 2025-2030 (USD MILLION)
  • TABLE 363. TURKEY CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 364. TURKEY CAS9 NUCLEASE MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 365. TURKEY CAS9 NUCLEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 366. TURKEY CAS9 NUCLEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 367. TURKEY CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 368. TURKEY CAS9 NUCLEASE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 369. ISRAEL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 370. ISRAEL CAS9 NUCLEASE MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 371. ISRAEL CAS9 NUCLEASE MARKET S